作者: Raje, Noopur ; Johnson, Patrick C. ; Cook, Daniella ; Birocchi, Filippo ; Lindell, Kevin ; Newcomb, Richard ; Jeffrey, Richard ; Choi, Bryan D. ; Hammond, Sarah P. ; Mount, Christopher W. ; Maus, Marcela V. ; Gallagher, Kathleen M. E. ; Harris, Deshea L. ; Armstrong, Alexander ; Escobar, Giulia ; Li, Alex ; Leick, Mark B. ; El-Jawahri, Areej ; Mucci, Adele ; Dhawale, Tejaswini M. ; Reddy, Shantan ; Luk, Samantha O. ; Dougan, Michael ; Nardi, Valentina ; Yee, Andrew J. ; Chen, Yi-Bin ; Cirstea, Diana ; Chaffee, Ryan ; Blumenberg, Viktoria ; Barselau, Alexis L. ; Bozym, David J. ; Roche, Aoife M. ; McFarland, Alexander G. ; Sohani, Aliyah R. ; Frigault, Matthew J. ; Emmanuel-Alejandro, Estelle ; Branagan, Andrew ; Graham, Charlotte E. ; Shih, Angela ; Puliafito, Benjamin R. ; Bushman, Frederic D.

Abstract:

Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.

2026-04-01·Med

Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease

Article

作者: Kusner, Linda L ; Kaminski, Henry J

Ruan and colleagues report that dual-target CD19/BCMA CAR-T cell therapy produced marked clinical improvement in highly refractory myasthenia gravis, with steroid discontinuation and minimal toxicity. Beyond symptom control, deep immune profiling revealed sustained B-cell depletion, reduced autoantibodies, and systemic immune reprogramming toward a less inflammatory state.

2026-03-01·BONE MARROW TRANSPLANTATION

Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy

Article

作者: Chang, Alex Hongsheng ; Feng, Jingjing ; Zhao, Xin ; Fu, Shan ; Zhao, Kui ; Zhang, Mingming ; Zhang, Yanlei ; Wang, Linqin ; Liu, Yinuo ; Zhao, Houli ; Zhang, Yafei ; Cui, Jiazhen ; Hong, Ruimin ; Xu, Huijun ; Huang, He ; Wu, Xiaoyu ; Li, Yixue ; Wei, Guoqing ; Xiao, Pingnan ; Liu, Kanfeng ; Hu, Yongxian

Patients with relapsed/refractory multiple myeloma (R/R MM) receiving chimeric antigen receptor (CAR) T-cell therapy are at high risk of toxicities, including cytokine release syndrome (CRS). The roles of positron emission-tomography computed tomography (PET/CT) in predicting these toxicities remain unclear. We retrospectively studied 62 patients with R/R MM who received B-cell maturation antigen (BCMA) CAR T-cell therapy at our center. Baseline metabolic tumor volume (MTV) of more than 107.2 cm³ and total lesion glycolysis (TLG) exceeding 406.5 were classified as high MTV and high TLG, respectively. Both high MTV (P = 0.008) and high TLG (P = 0.011) were identified as independent risk factors for the development of severe CRS classified as grade 3 to 4. Moreover, the administration of tocilizumab for the treatment of CRS was associated with high MTV (P = 0.005) or high TLG (P = 0.010). Notably, our multivariate Cox models that incorporated either MTV (P = 0.029) or TLG (P = 0.009) along with plasmacytoma types, high-risk cytogenetics, and high bone marrow plasma cell frequencies demonstrated strong predictive capabilities for the 5.3-year long-term OS. Therefore, baseline high MTV or TLG measured by PET/CT are recognized as adverse prognostic indicators for the incidence of severe CRS and poor outcomes in patients with R/R MM undergoing BCMA CAR T-cell therapy.

100 项与 BCMA-CAR-T cell(Takara Bio) 相关的药物交易

登录后查看更多信息